20:19 , Nov 27, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Mouse studies identified a bispecific mAb against EGFR and 4-1BB that could help treat colorectal cancer. The bispecific, trimeric mAb consisted of an anti-human EGFR single-domain antibody linked to the C-terminus of...
17:54 , Aug 29, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer Mouse studies identified a cyclic lipodepsipeptide (CLD) that could help treat cancer. In mice with mouse embryo fibroblast-induced foot tumors, a previously reported CLD containing a 4-amido-2,4-pentadienoate substructure decreased tumor growth compared with...
15:47 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Inflammation Patient sample and cell culture studies suggest nitro-fatty acids could help treat STING-associated vasculopathy with onset in infancy (SAVI), an inflammatory disease caused by gain-of-function STING mutations. In fibroblasts from SAVI patients, nitro-fatty...
19:11 , Mar 9, 2018 |  BC Week In Review  |  Clinical News

Gilead's TLR7 agonist shows promise against HIV in shock and kill combo in monkeys

Researchers showed that a broadly neutralizing antibody (bNAb) delayed HIV rebound in a "shock and kill" combination with toll-like receptor 7 (TLR7) agonist vesatolimod (GS-9620) from Gilead Sciences Inc. (NASDAQ:GILD) after discontinuation of antiretroviral therapy...
22:57 , Mar 5, 2018 |  BC Extra  |  Preclinical News

HIV shock and kill combo shows promise in monkeys

Researchers showed that a broadly neutralizing antibody (bNAb) delayed HIV rebound in a "shock and kill" combination with toll-like receptor 7 (TLR7) agonist vesatolimod (GS-9620) from Gilead Sciences Inc. (NASDAQ:GILD) after discontinuation of antiretroviral therapy...
19:21 , Jan 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Allergy Cell culture studies suggest a CD23-mimicking single-domain antibody against IgE could help treat allergy. The single-domain neutralizing antibody mimics CD23, the low-affinity Fc receptor for IgE, to bind IgE with a K d...
15:44 , Aug 11, 2017 |  BC Week In Review  |  Clinical News

Mologen's lefitolimod misses in extension for HIV infection

Mologen AG (Xetra:MGN) reported data from 12 patients with chronic HIV-1 infection on antiretroviral therapy (ART) in a 24-week extension of the open-label, Danish Phase Ib/IIa TEACH trial showing that twice-weekly 60 mg subcutaneous lefitolimod...
23:03 , Aug 9, 2017 |  BC Extra  |  Clinical News

Mologen sinks on lefitolimod HIV miss

Mologen AG (Xetra:MGN) dropped €0.81 (21%) to €3.06 on Wednesday after its lefitolimod (MGN1703) missed the primary endpoint in an extension of the Phase Ib/IIa TEACH trial to treat HIV infection in patients on antiretroviral...
23:05 , Feb 2, 2017 |  BC Innovations  |  Strategy

Cure cash

With the goal now to clear rather than just suppress HIV, Gilead Sciences Inc. is using a $22 million grant program to back the scientific strategies it thinks are most likely to empty the HIV...
07:00 , Sep 29, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CD163

Neurology INDICATION: Parkinson's disease (PD) Rat studies suggest CD163-targeting liposomes loaded with anti-inflammatory agents could help treat PD. In a rat model of PD, numbers of striatum-infiltrating CD163-positive macrophages were higher than in normal rats....